ASX Release

24 November 2026

NOTICE UNDER ASX LISTING RULE 3.10A

MELBOURNE, AUSTRALIA 24 November 2026: Arovella Therapeutics, (ASX: ALA), advises pursuant to ASX Listing Rule 3.10A that 371,187 Ordinary Shares are due to be released from voluntary escrow on 8 December 2026. These Ordinary Shares were issued on 8 December 2025 under the Company's Employee Share Option Plan.

Yours faithfully

Lachlan Mallia
Company Secretary
Arovella Therapeutics Ltd
investor@arovella.com

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumours, and autoimmune disease. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

For more information, visit www.arovella.com